Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Neoadjuvant CRT for Upper ESCC
NCT05541445Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Major Pathologic Response at 4 months. Status: unknown.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05541445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05541445.